Back to Search
Start Over
Two new treatment options for infections due to drug-resistant gram-positive cocci.
- Source :
-
Cleveland Clinic journal of medicine [Cleve Clin J Med] 2002 May; Vol. 69 (5), pp. 397-401, 405-13. - Publication Year :
- 2002
-
Abstract
- Gram-positive cocci, including enterococci and Staphylococcus aureus, have become the leading cause of hospital-acquired infections, and their resistance to antibiotics is increasing. Two important new drugs-quinupristin/dalfopristin (Synercid) and linezolid (Zyvox)-were designed specifically to treat infections due to drug-resistant gram-positive cocci. But their use must be tempered by their cost, toxicity, and concerns about further development of resistant strains.
- Subjects :
- Acetamides adverse effects
Acetamides therapeutic use
Anti-Bacterial Agents adverse effects
Anti-Bacterial Agents therapeutic use
Drug Interactions
Drug Resistance, Microbial
Drug Therapy, Combination adverse effects
Drug Therapy, Combination pharmacology
Enterococcus drug effects
Humans
Linezolid
Methicillin pharmacology
Methicillin therapeutic use
Oxazolidinones adverse effects
Oxazolidinones therapeutic use
Virginiamycin adverse effects
Virginiamycin pharmacology
Cross Infection drug therapy
Drug Therapy, Combination therapeutic use
Gram-Positive Bacterial Infections drug therapy
Gram-Positive Cocci drug effects
Virginiamycin therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0891-1150
- Volume :
- 69
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cleveland Clinic journal of medicine
- Publication Type :
- Academic Journal
- Accession number :
- 12022383
- Full Text :
- https://doi.org/10.3949/ccjm.69.5.397